Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
B2RTY4
UPID:
MYO9A_HUMAN
Alternative names:
Unconventional myosin-9a
Alternative UPACC:
B2RTY4; B0I1T5; C9IYB3; C9JA86; Q14787; Q3YLD7; Q3YLD8; Q6P986; Q9H8T5; Q9NTG2; Q9NUY2; Q9UEP3; Q9UNJ2
Background:
Unconventional myosin-IXa, also known as myosin-9a, is an actin-based motor molecule with ATPase activity, pivotal in intracellular movements. It plays a crucial role in regulating Rho by stimulating its GTPase activity in neurons, essential for neurite branching and motor neuron axon guidance.
Therapeutic significance:
Linked to Myasthenic syndrome, congenital, 24, presynaptic, unconventional myosin-IXa's understanding could pave the way for innovative therapeutic strategies targeting neuromuscular transmission disorders.